WuXi AppTec opens first cGMP biologics facility in China

China’s WuXi AppTec recently hosted an inaugural Global Monoclonal Antibody Summit in conjunction with the startup of its current Good Manufacturing Practice (cGMP) biologics manufacturing facility in the city of Wuxi. Attending the event were executives from global pharmaceutical and biotech companies, scientists and researchers in biologics and officials from the Chinese central and local governments.

WuXi AppTec has invested substantially in building its capabilities and capacity in biologics in the past few years. The current startup of its biologics manufacturing facility in Wuxi, the first in China to meet GMP standards of the USA, the European Union and China, marked another milestone for the company. This facility also is the first one globally to utilize 100% disposable equipment for biologics drug substance manufacturing.

"The establishment of this cGMP biologics facility has greatly improved WuXi's services in biologics manufacturing and further showcases our commitment to global clients," said Ge Li, chairman and chief executive of WuXi AppTec at the opening ceremony. "WuXi is determined to provide world-class services for anyone conducting research in biologics discovery, development and manufacturing including multinational and Chinese pharmaceutical and biotech companies," he added.